All Stories

  1. Neurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder
  2. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
  3. Post-acute COVID syndrome (long COVID): What should radiographers know and the potential impact for imaging services
  4. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
  5. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID
  6. STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol
  7. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
  8. Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
  9. Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
  10. The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program
  11. Treatment of myocardial ischaemia-reperfusion injury in patients with ST-segment elevation myocardial infarction: promise, disappointment, and hope
  12. New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice
  13. Carotid–femoral pulse wave velocity acquisition methods and their associations with cardiovascular risk factors and subclinical biomarkers of vascular health
  14. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
  15. Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example
  16. The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
  17. Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage
  18. An exploratory study of the relationship between systemic microcirculatory function and small solute transport in incident peritoneal dialysis patients
  19. 24-h Glycaemic profiles in peritoneal dialysis patients and non-dialysis controls with advanced kidney disease
  20. In vivo Measurement of Intraosseous Vascular Haemodynamic Markers in Human Bone Tissue Utilising Near Infrared Spectroscopy
  21. Cerebral small vessel disease, systemic vascular characteristics and potential therapeutic targets
  22. Development and presentation of an objective risk stratification tool for healthcare workers when dealing with the COVID-19 pandemic in the UK: risk modelling based on hospitalisation and mortality statistics compared with epidemiological data
  23. Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
  24. Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes
  25. Correction to: Diabetes, cardiovascular disease and the microcirculation
  26. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults
  27. Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
  28. Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019–2020 Season
  29. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study
  30. Vaccinating Adolescents and Children Significantly Reduces Covid-19 Morbidity and Mortality Across All Ages: A Population-Based Modeling Study Using the UK as an Example
  31. The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID
  32. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review
  33. The impact of COVID-19 on Medical education and Medical Students. How and when can they return to placements?
  34. Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications
  35. Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol
  36. What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
  37. Development and Presentation of an Objective Risk Stratification Tool for healthcare workers when dealing with the COVID-19 pandemic in the UK: Risk modelling based on hospitalisation and mortality statistics compared to epidemiological data
  38. The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement
  39. Predicting incident delirium diagnoses using data from primary-care electronic health records
  40. Weight change and sulfonylurea therapy are related to 3 year change in microvascular function in people with type 2 diabetes
  41. The systemic microcirculation in dialysis populations
  42. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality
  43. A Mendelian Randomization Study Provides Evidence That Adiposity and Dyslipidemia Lead to Lower Urinary Albumin-to-Creatinine Ratio, a Marker of Microvascular Function
  44. An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabet Med 2019; 36: 1063–1071
  45. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study
  46. Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK
  47. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
  48. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting
  49. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
  50. Association of blood pressure with clinical outcomes in older adults with chronic kidney disease
  51. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
  52. ‘One-size-fits-all’ treatment targets harm frail older patients with diabetes
  53. Tackling clinical inertia: Use of coproduction to improve patient engagement
  54. Measurement of Wall Shear Stress Exerted by Flowing Blood in the Human Carotid Artery: Ultrasound Doppler Velocimetry and Echo Particle Image Velocimetry
  55. Use of near-infrared systems for investigations of hemodynamics in human in vivo bone tissue: A systematic review
  56. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative
  57. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes
  58. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults
  59. Diabetes, cardiovascular disease and the microcirculation
  60. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial
  61. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia
  62. The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control
  63. Smoking cessation and outcome after ischemic stroke or TIA
  64. Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes
  65. Echo Particle Image Velocimetry for Estimation of Carotid Artery Wall Shear Stress: Repeatability, Reproducibility and Comparison with Phase-Contrast Magnetic Resonance Imaging
  66. Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration
  67. Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study
  68. Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
  69. Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin – Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
  70. Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
  71. Outcomes of Treated Hypertension at Age 80 and Older: Cohort Analysis of 79,376 Individuals
  72. The effects of lumbar sympathectomy on bone and soft tissue haemodynamics of the leg recorded using near infrared spectroscopy: A case report
  73. [PP.11.05] RESERVOIR-PRESSURE ANALYSIS IN TYPE 2 DIABETES INDIVIDUALS WITH CARDIOVASCULAR DISEASE
  74. Microalbuminuria could improve risk stratification in patients with TIA and minor stroke
  75. Glucose dysregulation and its effect on peritoneal dialysis patients
  76. Reactivity to low-flow as a potential determinant for brachial artery flow-mediated vasodilatation
  77. Echogenicity of the Common Carotid Artery Intima–Media Complex in Stroke
  78. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
  79. Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
  80. Type 2 diabetes exacerbates carotid artery echogenicity and central artery stiffness in middle-aged and older individuals
  81. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes
  82. PP.20.26
  83. Blood Oxygen Saturation After Ischemia is Altered With Abnormal Microvascular Reperfusion
  84. 53 * THE CORRELATION BETWEEN PATIENTS, PATIENT'S RELATIVES AND HEALTHCARE PROFESSIONALS INTERPRETATION OF QUALITY OF LIFE - A PROSPECTIVE STUDY
  85. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial
  86. A Review of the Mechanisms, Diagnosis and Preventative Treatment of Osteoporotic Fragility Fractures in Patients With Type 2 Diabetes Mellitus
  87. Reactivity to low-flow in the brachial artery: A potential determinant for flow-mediated dilatory response
  88. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
  89. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
  90. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus
  91. P083: The correlation between patients, patient's relatives and healthcare professionals interpretation of quality of life – A prospective study
  92. Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
  93. 242. Turning of the Tide: Does Tidemark Advancement Perpetuate Osteoarthritis
  94. Attenuated Systemic Microvascular Function in Men with Coronary Artery Disease is Associated with Angina but not Explained by Atherosclerosis
  95. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
  96. Echogenicity of the common carotid artery intima-media complex in stroke
  97. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
  98. Computed tomography to diagnose coronary artery disease: A reduction in radiation dose increases applicability
  99. Microalbuminuria could improve risk prediction of stroke in patients with transient ischaemic attacks and minor strokes
  100. Influence of estimated wall shear rate indices on carotid artery intima-media thickness and intima-media complex echogenicity
  101. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
  102. Impaired post-ischaemic microvascular hyperaemia in Indian Asians is unexplained by diabetes or other cardiovascular risk factors
  103. Microcirculation on a Large Scale: Techniques, Tactics and Relevance of Studying the Microcirculation in Larger Population Samples
  104. The relationship between brachial artery flow-mediated dilation and shear rate in individuals with increased cardiovascular risk
  105. Arterial Wall Shear Stress Measurement In Vivo Using Echo Particle Image Velocimetry (Echo PIV)
  106. In Vitro and Preliminary In Vivo Validation of Echo Particle Image Velocimetry in Carotid Vascular Imaging
  107. ALBUMIN:CREATININE RATIO PREDICTS MORTALITY AFTER STROKE: ANALYSIS OF THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
  108. Age-related change in endothelial and microvessel function and therapeutic consequences
  109. Associations between cardiac target organ damage and microvascular dysfunction: the role of blood pressure
  110. Attenuation of microvascular function in those with cardiovascular disease is similar in patients of Indian Asian and European descent
  111. Noninvasive wall shear stress measurements in human carotid artery using echo particle image velocimetry: Initial clinical studies
  112. Comparison of the retinal microvasculature in European and African-Caribbean people with diabetes
  113. In Vivo Validation of Echo Partical Image Velocimetry (Echo PIV) in Human Carotid Arteries Using Phase-Contrast MRI
  114. Human endothelial function and microvascular ageing
  115. Increased Arterial Stiffness in Europeans and African Caribbeans With Type 2 Diabetes Cannot be Accounted for by Conventional Cardiovascular Risk Factors
  116. Differences in the association between type 2 diabetes and impaired microvascular function among Europeans and African Caribbeans
  117. Ethnic differences in microvascular structure and function
  118. Albumin Excretion Rate and Cardiovascular Risk: Could the Association Be Explained by Early Microvascular Dysfunction?
  119. Ethnic differences in skin microvascular function and their relation to cardiac target-organ damage
  120. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure
  121. Ethnic differences in vascular stiffness and relations to hypertensive target organ damage
  122. Review: The renin-angiotensin-aldosterone system and the eye in diabetes
  123. Chronic pain, bereavement and overdose in a depressed elderly woman
  124. Severe Adrenal Suppression by Steroid Nasal Drops